Efficacy and Safety of PARPi to Treat Pancreatic Cancer

Study ID
NCT02511223

Study type
Interventional

Study phase
Phase 2

Study status
Completed

Trial Acronym

Trial Summary

This is an open label, single arm, phase II trial of Olaparib for (PDAC) pancreatic ductal adenocarcinoma patients with BRCAness (breast cancer gene). All study subjects will receive Olaparib in a dose of 300 mg p.o twice daily. Treatment will continue until progression, intolerable toxicity or as per patient preference. Primary objective: To determine the efficacy of Olaparib monotherapy in stage IV pancreatic ductal adenocarcinoma (PDAC)with (BRCAness) BRCA -Breast Cancer susceptibility gene.

More informations

Trial Starting Date

Jul 31,2016

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit